Claims:

1. Use of a therapeutic combination in the manufacture of a medicament for the treatment of a hyperproliferative disorder, wherein the use comprises administering a therapeutic combination as a combined formulation or by alternation to a mammal, wherein the therapeutic combination comprises a therapeutically effective amount of trastuzumab-MCC-DM1, and a therapeutically effective amount of pertuzumab; wherein administration of the therapeutic combination results in a synergistic effect.

2. The use of claim 1, wherein the therapeutically effective amount of trastuzumab-MCC-DM1 and the therapeutically effective amount of pertuzumab are to be administered as a combined formulation.

3. The use of claim 1, wherein the therapeutically effective amount of trastuzumab-MCC-DM1 and the therapeutically effective amount of pertuzumab are to be administered by alternation.

4. The use of claim 3 wherein the mammal is to be administered pertuzumab and then subsequently administered trastuzumab-MCC-DM1.

5. The use of claim 2, wherein the therapeutic combination is to be administered at about three week intervals to a human with the hyperproliferative disorder.

6. The use of any one of the preceding claims, wherein trastuzumab-MCC-DM1 is to be administered at intervals from about one week to three weeks to a human with the hyperproliferative disorder.

7. The use of claim 6, wherein the trastuzumab-MCC-DM1 is to be administered no more frequently than every 3 weeks at a dose of 2.4, 3.0 or 3.6 mg/kg intravenously.

8. The use of any one of the preceding claims, wherein the amount of trastuzumab-MCC-DM1 and the amount of pertuzumab are each from about 1 mg to about 1000 mg and the amount of trastuzumab-MCC-DM1 and the amount of pertuzumab are in a ratio of about 1:10 to about 10:1 by weight.

9. The use of any one of the preceding claims, wherein the hyperproliferative disorder is cancer expressing ErbB2.

10. The use of any one of the preceding claims, wherein the mammal is a HER2 positive patient.

11. The use of any one of the preceding claims, wherein the HER2 positive patient has received trastuzumab or lapatinib therapy.

12. A pharmaceutical composition comprising trastuzumab-MCC-DM1, pertuzumab,; and one or more pharmaceutically acceptable carrier, glidant, diluent, or excipient, wherein administration of the pharmaceutical composition results in a synergistic effect.

13. The pharmaceutical composition of claim 12 comprising a pharmaceutically acceptable glidant selected from silicon dioxide, powdered cellulose, microcrystalline cellulose, metallic stearates, sodium aluminosilicate, sodium benzoate, calcium carbonate, calcium silicate, com starch, magnesium carbonate, asbestos free talc, stearowet C, starch, starch 1500, magnesium lauryl sulfate, magnesium oxide, and combinations thereof.

14. Use of a therapeutic combination in the manufacture of a medicament for the treatment of breast cancer, wherein the therapeutic combination is administered to a mammal as a combined formulation or by alternation, and wherein the therapeutic combination comprises a therapeutically effective amount of trastuzumab-MCC-DM1, and a therapeutically effective amount of pertuzumab, wherein administration of the therapeutic combination results in a synergistic effect.

15. A method for determining a therapeutic combination of trastuzumab-MCC-DM1, and pertuzumab to be used for the treatment of cancer comprising:

a) treating an in vitro tumor cell line with a therapeutic combination of trastuzumab-MCC-DM1, and pertuzumab, and

b) measuring a synergistic or non-synergistic effect;

whereby a synergistic therapeutic combination for the treatment of cancer is determined.

Claims:

1. Use of a therapeutic combination in the manufacture of a medicament for the treatment of a hyperproliferative disorder, wherein the therapeutic combination is to be administered as a combined formulation or by alternation to a mammal, wherein the therapeutic combination comprises a therapeutically effective amount of trastuzumab-MCC-DM1, and a therapeutically effective amount of pertuzumab; wherein administration of the therapeutic combination results in a synergistic effect.

2. The use of claim 1, wherein the therapeutically effective amount of trastuzumab-MCC-DM1 and the therapeutically effective amount of pertuzumab are to be administered as a combined formulation.

3. The use of claim 1, wherein the therapeutically effective amount of trastuzumab-MCC-DM1 and the therapeutically effective amount of pertuzumab are to be administered by alternation.

4. The use of claim 3 wherein the mammal is to be administered pertuzumab and then subsequently administered trastuzumab-MCC-DM1.

5. The use of claim 2, wherein the therapeutic combination is to be administered at about three week intervals to a human with the hyperproliferative disorder.

6. The use of any one of the preceding claims, wherein trastuzumab-MCC-DM1 is to be administered at intervals from about one week to three weeks to a human with the hyperproliferative disorder.

7. The use of claim 6, wherein the trastuzumab-MCC-DM1 is to be administered no more frequently than every 3 weeks at a dose of 2.4, 3.0 or 3.6 mg/kg intravenously.

8. The use of any one of the preceding claims, wherein the amount of trastuzumab-MCC-DM1 and the amount of pertuzumab are each from about 1 mg to about 1000 mg and the amount of trastuzumab-MCC-DM1 and the amount of pertuzumab are in a ratio of about 1:10 to about 10:1 by weight.

9. The use of any one of the preceding claims, wherein the hyperproliferative disorder is cancer expressing ErbB2.

10. The use of any one of the preceding claims, wherein the mammal is a HER2 positive patient.

11. The use of any one of the preceding claims, wherein the HER2 positive patient has received trastuzumab or lapatinib therapy.

12. A pharmaceutical composition comprising trastuzumab-MCC-DM1, pertuzumab,; and one or more pharmaceutically acceptable carrier, glidant, diluent, or excipient, wherein administration of the pharmaceutical composition results in a synergistic effect.

13. The pharmaceutical composition of claim 12 comprising a pharmaceutically acceptable glidant selected from silicon dioxide, powdered cellulose, microcrystalline cellulose, metallic stearates, sodium aluminosilicate, sodium benzoate, calcium carbonate, calcium silicate, com starch, magnesium carbonate, asbestos free talc, stearowet C, starch, starch 1500, magnesium lauryl sulfate, magnesium oxide, and combinations thereof.

14. Use of a therapeutic combination in the manufacture of a medicament for the treatment of breast cancer, wherein the therapeutic combination is to be administered to a mammal as a combined formulation or by alternation, and wherein the therapeutic combination comprises a therapeutically effective amount of trastuzumab-MCC-DM1, and a therapeutically effective amount of pertuzumab, wherein administration of the therapeutic combination results in a synergistic effect.

15. A method for determining a therapeutic combination of trastuzumab-MCC-DM1, and pertuzumab to be used for the treatment of cancer comprising:

a) treating an in vitro tumor cell line with a therapeutic combination of trastuzumab-MCC-DM1, and pertuzumab, and

b) measuring a synergistic or non-synergistic effect;

whereby a synergistic therapeutic combination for the treatment of cancer is determined.